PRELUDE THERAPEUTICS INC (PRLD) Stock Fundamental Analysis

NASDAQ:PRLD • US74065P1012

2.86 USD
+0.09 (+3.25%)
Last: Feb 24, 2026, 08:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

PRLD gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 521 industry peers in the Biotechnology industry. PRLD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PRLD is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year PRLD has reported negative net income.
  • In the past year PRLD has reported a negative cash flow from operations.
  • In the past 5 years PRLD always reported negative net income.
  • In the past 5 years PRLD always reported negative operating cash flow.
PRLD Yearly Net Income VS EBIT VS OCF VS FCFPRLD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • The Return On Assets of PRLD (-134.21%) is worse than 81.57% of its industry peers.
  • Looking at the Return On Equity, with a value of -217.26%, PRLD is doing worse than 69.67% of the companies in the same industry.
Industry RankSector Rank
ROA -134.21%
ROE -217.26%
ROIC N/A
ROA(3y)-56.23%
ROA(5y)-46.15%
ROE(3y)-69.07%
ROE(5y)-54.62%
ROIC(3y)N/A
ROIC(5y)N/A
PRLD Yearly ROA, ROE, ROICPRLD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for PRLD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRLD Yearly Profit, Operating, Gross MarginsPRLD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • PRLD does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, PRLD has more shares outstanding
  • The number of shares outstanding for PRLD has been increased compared to 5 years ago.
  • The debt/assets ratio for PRLD is higher compared to a year ago.
PRLD Yearly Shares OutstandingPRLD Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
PRLD Yearly Total Debt VS Total AssetsPRLD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • PRLD has an Altman-Z score of -11.25. This is a bad value and indicates that PRLD is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -11.25, PRLD is doing worse than 74.28% of the companies in the same industry.
  • There is no outstanding debt for PRLD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.25
ROIC/WACCN/A
WACC8.67%
PRLD Yearly LT Debt VS Equity VS FCFPRLD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

  • PRLD has a Current Ratio of 3.21. This indicates that PRLD is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 3.21, PRLD is doing worse than 62.38% of the companies in the same industry.
  • PRLD has a Quick Ratio of 3.21. This indicates that PRLD is financially healthy and has no problem in meeting its short term obligations.
  • PRLD has a Quick ratio (3.21) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.21
Quick Ratio 3.21
PRLD Yearly Current Assets VS Current LiabilitesPRLD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 16.95% over the past year.
EPS 1Y (TTM)16.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.53%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%116.67%

3.2 Future

  • Based on estimates for the next years, PRLD will show a small growth in Earnings Per Share. The EPS will grow by 7.99% on average per year.
  • The Revenue is expected to grow by 103.00% on average over the next years. This is a very strong growth
EPS Next Y24.65%
EPS Next 2Y16.89%
EPS Next 3Y20.24%
EPS Next 5Y7.99%
Revenue Next Year-100%
Revenue Next 2Y400%
Revenue Next 3Y268.4%
Revenue Next 5Y103%

3.3 Evolution

PRLD Yearly Revenue VS EstimatesPRLD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M
PRLD Yearly EPS VS EstimatesPRLD Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for PRLD. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PRLD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRLD Price Earnings VS Forward Price EarningsPRLD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRLD Per share dataPRLD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as PRLD's earnings are expected to grow with 20.24% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.89%
EPS Next 3Y20.24%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for PRLD!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PRELUDE THERAPEUTICS INC

NASDAQ:PRLD (2/24/2026, 8:00:01 PM)

2.86

+0.09 (+3.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-09
Inst Owners32.67%
Inst Owner Change3.74%
Ins Owners9.91%
Ins Owner Change0.18%
Market Cap179.81M
Revenue(TTM)7.00M
Net Income(TTM)-127.17M
Analysts84.44
Price Target4.08 (42.66%)
Short Float %6.08%
Short Ratio4.66
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.38%
Min EPS beat(2)8.54%
Max EPS beat(2)30.21%
EPS beat(4)4
Avg EPS beat(4)17.61%
Min EPS beat(4)8.54%
Max EPS beat(4)30.21%
EPS beat(8)7
Avg EPS beat(8)12.41%
EPS beat(12)11
Avg EPS beat(12)13.6%
EPS beat(16)14
Avg EPS beat(16)10.99%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)81.29%
EPS NY rev (1m)0%
EPS NY rev (3m)9.58%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)300%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 25.69
P/FCF N/A
P/OCF N/A
P/B 3.07
P/tB 3.07
EV/EBITDA N/A
EPS(TTM)-1.47
EYN/A
EPS(NY)-1.07
Fwd EYN/A
FCF(TTM)-1.6
FCFYN/A
OCF(TTM)-1.59
OCFYN/A
SpS0.11
BVpS0.93
TBVpS0.93
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -134.21%
ROE -217.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-56.23%
ROA(5y)-46.15%
ROE(3y)-69.07%
ROE(5y)-54.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.73%
Cap/Sales 1.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.21
Quick Ratio 3.21
Altman-Z -11.25
F-Score4
WACC8.67%
ROIC/WACCN/A
Cap/Depr(3y)190.81%
Cap/Depr(5y)187.88%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.53%
EPS Next Y24.65%
EPS Next 2Y16.89%
EPS Next 3Y20.24%
EPS Next 5Y7.99%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%116.67%
Revenue Next Year-100%
Revenue Next 2Y400%
Revenue Next 3Y268.4%
Revenue Next 5Y103%
EBIT growth 1Y-5.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-15.26%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y8.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y5.88%
OCF growth 3YN/A
OCF growth 5YN/A

PRELUDE THERAPEUTICS INC / PRLD FAQ

What is the fundamental rating for PRLD stock?

ChartMill assigns a fundamental rating of 2 / 10 to PRLD.


What is the valuation status for PRLD stock?

ChartMill assigns a valuation rating of 1 / 10 to PRELUDE THERAPEUTICS INC (PRLD). This can be considered as Overvalued.


What is the profitability of PRLD stock?

PRELUDE THERAPEUTICS INC (PRLD) has a profitability rating of 0 / 10.


How financially healthy is PRELUDE THERAPEUTICS INC?

The financial health rating of PRELUDE THERAPEUTICS INC (PRLD) is 5 / 10.